#bristol-myers-squibb (2 Posts)
-
Bristol-Myers’ Schizophrenia Drug Falls Short in Key Trial Bristol-Myers Squibb's Cobenfy trial for schizophrenia failed to show significant results, prompting future data presentation.
-
FDA Gives Green Light to Subcutaneous Opdivo – What This Means for Cancer Patients FDA approves subcutaneous Opdivo, enhancing cancer treatment with similar efficacy to intravenous form and improved patient convenience.
Hot Topics